Generics in China

Generics in China


  • Products Id :- OHME8752
  • |
  • Pages: 34
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in China

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in China

Leading company profiles reveal details of key generics market players' global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the China generics market with five year forecasts by both value and volume

Synopsis

Essential resource for top-line data and analysis covering the China generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons to Buy

What was the size of the China generics market by value in 2016?

What will be the size of the China generics market in 2021?

What factors are affecting the strength of competition in the China generics market?

How has the market performed over the last five years?

How large is China's generics market in relation to its regional counterparts?

Key Highlights

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Chinese generics market is expected to generate total revenues of $63.1bn in 2016, representing a compound annual growth rate (CAGR) of 15.5% between 2012 and 2016.

Market consumption volume is forecast to decline with a compound annual rate of change (CARC) of -0.2% between 2012 and 2016, to reach a total of 94.3% of total pharma volume in 2016.

The Chinese government has announced an ambitious universal healthcare program that aims to provide healthcare for the country's 1.3 billion inhabitants. This should ensure further growth for the market.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Executive Summary

Market value

Market value forecast

Market volume

Market volume forecast

Geography segmentation

Market rivalry

Market Overview

Market definition

Market analysis

Market Data

Market value

Market volume

Market Segmentation

Geography segmentation

Market Outlook

Market value forecast

Market volume forecast

Five Forces Analysis

Summary

Buyer power

Supplier power

New entrants

Threat of substitutes

Degree of rivalry

Leading Companies

China Grand Pharmaceutical and Healthcare Holdings Limited

Mylan Inc.

Sandoz International GmbH

Teva Pharmaceutical Industries Limited

Macroeconomic Indicators

Country data

Methodology

Industry associations

Related MarketLine research

Appendix

About MarketLine

Figure 1: China generics market value: $ billion, 2012-16(e)

Figure 2: China generics market volume: % of total pharma volume, 2012-16(e)

Figure 3: China generics market geography segmentation: % share, by value, 2016(e)

Figure 4: China generics market value forecast: $ billion, 2016-21

Figure 5: China generics market volume forecast: % of total pharma volume, 2016-21

Figure 6: Forces driving competition in the generics market in China, 2016

Figure 7: Drivers of buyer power in the generics market in China, 2016

Figure 8: Drivers of supplier power in the generics market in China, 2016

Figure 9: Factors influencing the likelihood of new entrants in the generics market in China, 2016

Figure 10: Factors influencing the threat of substitutes in the generics market in China, 2016

Figure 11: Drivers of degree of rivalry in the generics market in China, 2016

Figure 12: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability

Figure 13: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

Figure 14: Mylan Inc.: revenues & profitability

Figure 15: Mylan Inc.: assets & liabilities

Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities

Table 1: China generics market value: $ billion, 2012-16(e)

Table 2: China generics market volume: % of total pharma volume, 2012-16(e)

Table 3: China generics market geography segmentation: $ billion, 2016(e)

Table 4: China generics market value forecast: $ billion, 2016-21

Table 5: China generics market volume forecast: % of total pharma volume, 2016-21

Table 6: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts

Table 7: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)

Table 8: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)

Table 9: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios

Table 10: Mylan Inc.: key facts

Table 11: Mylan Inc.: key financials ($)

Table 12: Mylan Inc.: key financial ratios

Table 13: Sandoz International GmbH: key facts

Table 14: Teva Pharmaceutical Industries Limited: key facts

Table 15: Teva Pharmaceutical Industries Limited: key financials ($)

Table 16: Teva Pharmaceutical Industries Limited: key financial ratios

Table 17: China size of population (million), 2012-16

Table 18: China gdp (constant 2005 prices, $ billion), 2012-16

Table 19: China gdp (current prices, $ billion), 2012-16

Table 20: China inflation, 2012-16

Table 21: China consumer price index (absolute), 2012-16

Table 22: China exchange rate, 2012-16

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

China Grand Pharmaceutical and Healthcare Holdings Limited, Mylan Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited

Generics, MarketLine, China

select a license
Single User License
USD 350 INR 24976
Site License
USD 700 INR 49952
Corporate User License
USD 1050 INR 74928

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com